1. Introduction {#sec1-cancers-12-00730}
===============

Gastrointestinal stromal tumours (GISTs) are found throughout the gastrointestinal tract and arise from interstitial cells of Cajal \[[@B1-cancers-12-00730]\]. Their estimated incidence is 10--15 per million \[[@B2-cancers-12-00730]\]. GIST patients have a median age at diagnosis of 65 years, and less than 10% are diagnosed before the age of 40 \[[@B3-cancers-12-00730],[@B4-cancers-12-00730],[@B5-cancers-12-00730]\].

The distinct presentation of paediatric GISTs is well described in the literature. While GISTs in adults arise in the stomach (40--60%) or in the small intestine (25--40%), in children, the stomach (90%) is the predominant site of origin, and multifocal GISTs are common \[[@B6-cancers-12-00730],[@B7-cancers-12-00730]\]. Furthermore, in children, GISTs have a female predilection \[[@B8-cancers-12-00730]\] and are more often associated with genetic syndromes, such as the Carney--Stratakis syndrome, Carney's triad syndrome and Neurofibromatosis type 1 (NF1) \[[@B9-cancers-12-00730],[@B10-cancers-12-00730],[@B11-cancers-12-00730]\].

Regarding mutational status, adult GISTs are commonly driven by activating mutations in either the *KIT* proto-oncogene (75%) or the *PDGFRA* (platelet-derived growth factor receptor A) oncogene (15%) \[[@B1-cancers-12-00730],[@B12-cancers-12-00730],[@B13-cancers-12-00730]\], and 10% were formerly named wildtype (WT) for *KIT* and *PDGFRA* \[[@B14-cancers-12-00730]\]. However, genetic research has unveiled other sporadic genetic alterations leading to GISTs, including RAS pathway gene mutations and mutations in the four succinate dehydrogenase (SDH) subunits \[[@B15-cancers-12-00730],[@B16-cancers-12-00730],[@B17-cancers-12-00730]\]. Therefore, the description WT GIST is disappearing, and it is now common practice for oncologists to describe which genetic alterations patients have been tested for \[[@B18-cancers-12-00730]\]. In contrast to the molecular characteristics of adults with GIST, children are *KIT* and *PDGFRA* WT in the vast majority (85--90%) \[[@B7-cancers-12-00730],[@B19-cancers-12-00730],[@B20-cancers-12-00730],[@B21-cancers-12-00730],[@B22-cancers-12-00730]\]. Finally, metastases in adults are mostly located intra-abdominally \[[@B1-cancers-12-00730],[@B23-cancers-12-00730]\], whereas, in children, lymph node and lung metastases are more common \[[@B24-cancers-12-00730]\].

In addition to the classical paediatric and adult GIST presentation as defined above, a rare 'paediatric-type' presentation of GIST in (young) adults has been described in the literature, as well. Despite their adult age, these 'paediatric-type' GISTs are *KIT/PDGFR* WT and present with gastric lesions with multinodular or plexiform growth pattern and epithelioid or mixed cell histology. The 'paediatric-type' GIST predominantly affects women, often metastasizes to the lymph nodes and has a relatively indolent course of disease \[[@B25-cancers-12-00730]\].

The young adult (YA) population has gained recognition in oncological research as a group with not only specific psychosocial needs but also distinct biological features \[[@B26-cancers-12-00730],[@B27-cancers-12-00730],[@B28-cancers-12-00730]\]. The literature on both clinical and biological GIST characteristics in YA is scarce. This retrospective cohort study aims to describe the clinical, pathological and molecular characteristics of GIST in YA patients.

2. Results {#sec2-cancers-12-00730}
==========

2.1. Patient Characteristics {#sec2dot1-cancers-12-00730}
----------------------------

From 1010 patients registered in the Dutch GIST Registry (DGR) in March 2019, 52 YA patients (aged 18 to 40 years, 5%) were identified ([Table 1](#cancers-12-00730-t001){ref-type="table"}). A small majority was male (54%), and the median age at diagnosis was 35 years (range 18--40). The main primary tumour locations were stomach (46%) and small intestine (ileum/jejunum/duodenum, 46%); median tumour size at diagnosis was 60 mm; and 87% had local disease at diagnosis. Two patients had multifocal GIST: one patient with a germline mutation (small bowel) and one patient without a known familial syndrome (stomach). Four YA patients had a known genetic predisposition for GIST, and three patients had a second malignancy (one patient had melanoma, one patient malignant peripheral neural sheath tumour (MPNST) and one patient also had breast and thyroid cancer). Most of the metastases that occurred were intra-abdominal/peritoneal or in the liver, with only one case of lymph node metastases. The most common symptom was active gastrointestinal bleeding (22%). In eight asymptomatic patients, the GIST was a coincidental finding. According to the Miettinen risk classification, 21 patients had at baseline a high-risk tumour (41%).

2.2. Pathology {#sec2dot2-cancers-12-00730}
--------------

The histology of the primary tumours was predominantly spindle cell (76%), and the baseline mitotic rate was low in 69% ([Table 2](#cancers-12-00730-t002){ref-type="table"}). GIST genetic profiles were reported as *KIT* mutation 69%, *PDGFRA* mutation 6%, SDH deficient 8%, NF1 associated 4%, *ETV6-NTRK3* (translocation-Ets-leukaemia virus and neurotrophic tyrosine kinase, only tested in one of the WT patients) gene fusion 2%, quadruple WT 6%, triple WT 2% and *KIT/PDGFRA* WT 2%. The WT tumours were located in the stomach (4/5) and in the small intestine (1/5). Altogether, 25% of the patients had a non-*KIT/PDGFR* mutation. One patient had a double primary mutation: *KIT* exon 11 and *KIT* exon 9.

2.3. Treatment {#sec2dot3-cancers-12-00730}
--------------

Patients in Dutch GIST centres are generally treated according to standard guidelines. Of all YA patients in this cohort, 14 received neoadjuvant treatment (30%). Of the 45 patients with localized disease, three did not undergo surgery, as a result of progressive disease on neoadjuvant therapy (two) or comorbidities (one). Two patients received surgery of their primary tumour in the metastatic, emergency setting. In total, 44 patients underwent surgery of the primary tumour (85%) ([Figure 1](#cancers-12-00730-f001){ref-type="fig"}). In eight patients, emergency surgery was performed due to perforation or active bleeding (six small intestine; two gastric). The resection margins were microscopically free from tumour in 93%, and five patients (11%) had complications, with none requiring further surgery. Of the 44 surgically treated patients, seven patients received neoadjuvant and adjuvant treatment and 12 received adjuvant treatment only.

2.4. Outcome {#sec2dot4-cancers-12-00730}
------------

With a median follow-up time of 52 months (95% Confidence Interval (CI): 31.5--72.5), the median overall survival (OS) for the YA patients was 8.9 years (95% CI: 7.4--10.4), with an estimated five-year survival rate of 85% (95% CI: 71.6--97.5). Of the 44 patients with resection of the primary tumour, 13 (30%) developed recurrence: two local, eight distant and three both local and distant recurrences.

The median follow-up time in older adults (OA) was 37 months (95% CI: 33.0--41.0). The median OS time was not reached, but the estimated five-year survival rate was 76% (95% CI: 72.2--79.7). There was no significant difference in OS between the YA and OA patients (*p* = 0.10) ([Figure 2](#cancers-12-00730-f002){ref-type="fig"}).

2.5. Impact of GIST on Life {#sec2dot5-cancers-12-00730}
---------------------------

In 56% of all patients, the psychosocial impact of their disease on life was both discussed by the oncologist and noted in the electronic patient record (EPR). This was 15% for the possible influence of the disease or treatment on fertility. The (in)ability to work/study was discussed and noted in 12 (46%) of the 26 patients receiving (neo) adjuvant therapy; seven patients (58%) had no limitations, four reported to be working/studying less than before diagnosis; and one could no longer continue work/study. For the 18 YA patients treated in the palliative setting, (in)ability to work/study was discussed and noted in eight (44%), of which one (13%) reported no limitations; five were (63%) studying/working less than before; and two (25%) stopped working/studying altogether. Eleven patients were referred to a clinical geneticist.

2.6. Comparison of Age Groups {#sec2dot6-cancers-12-00730}
-----------------------------

### 2.6.1. Comparison within the YA Cohort {#sec2dot6dot1-cancers-12-00730}

Group 1 (age 18--29 years, median 26) consisted of 15 patients, and group 2 (30--40 years, median 38) of 37 patients. No significant differences in clinical and tumour characteristics were found between the two YA age subgroups ([Table 3](#cancers-12-00730-t003){ref-type="table"}). Furthermore, no differences were found in OS (*p* = 0.81) nor in RFS (*p* = 0.75). Concerning the mutation distribution among the YA cohort, no clear turning point was found where more wildtypes in younger patients (as in paediatric population) shifted to more *KIT* mutated patients in older patients (as in adult population) ([Figure 3](#cancers-12-00730-f003){ref-type="fig"}).

### 2.6.2. Comparison between the YA and OA Patients {#sec2dot6dot2-cancers-12-00730}

The OA age group consisted of 958 patients ([Table 4](#cancers-12-00730-t004){ref-type="table"}). Tumours were significantly more often localized in the small intestine in the YA age group, as compared to the OA age group (46% vs. 28%, *p* = 0.03). YA patients had a syndromic presentation more often than the OA age group (*p* = 0.047). Furthermore, YA patients significantly more often had non-*KIT/PDGFRA* positive tumours than patients in the OA group (25% vs. 11%, respectively; *p* = 0.008). Concerning treatment, YA patients tended to have surgery in an emergency setting more often than OA patients (18% vs. 9%, *p* = 0.06) ([Figure 1](#cancers-12-00730-f001){ref-type="fig"}). YA patients did not present more often with metastatic disease compared to OA (13.5% vs. 24.6%, *p* = 0.09). Furthermore, no significant differences were found between the two groups in gender, primary tumour size, risk classification, histology, baseline mitotic rate or the number of patients receiving surgery.

3. Discussion {#sec3-cancers-12-00730}
=============

This study shows that GIST at YA age is rare, representing only 5% of a large database. Paediatric GISTs have a female predilection and are rarely *KIT/PDGFRA* mutated \[[@B6-cancers-12-00730]\]. With an almost equal gender distribution and increased presence of *KIT* or *PDGFRA* mutations, YA GISTs differ from paediatric GIST. However, YA GISTs are also not fully similar to the typical adult GISTs either, as they have a lower percentage of *KIT* and *PDGFRA* mutations (76% vs. 90%) and are more frequently located in the small intestine (46% vs. 28%). Within the YA age group, we could not demonstrate a clear turning point in age at which the mutational status shifted from WT to *KIT/PDGFRA* mutation, but that may be due to the still relatively small number of YA patients.

Comparison of the data from this study with age-related GIST data in the existing literature is challenging. This is due to the scarcity of GIST data in the YA population, the divergent composition of age-groups studied and the incomplete reporting on mutational status. Three studies reported on individual patients, and we used these data to construct a YA (18--29) and a paediatric age group (\<18) \[[@B19-cancers-12-00730],[@B22-cancers-12-00730],[@B29-cancers-12-00730]\]. Fero et al. studied a large AYA population (13--39) and an OA population (≥40); however, they did not report on mutational status \[[@B30-cancers-12-00730]\] ([Supplementary Table S1](#app1-cancers-12-00730){ref-type="app"}). The almost-equal gender distribution in the YA and OA cohort of this study is in accordance with the large AYA and OA population studied by Fero et al. \[[@B30-cancers-12-00730]\]. Small intestine localisation seems to be less prevalent in the OA population compared with the YA population of this study, which is in line with the previous literature. Furthermore, this study confirmed that YA patients do not significantly more often present with metastatic disease compared to the OA population.

Concerning the mutational status, which was only scarcely reported before, our results were similar to the very small population (*n* = 30) of the combined studies of Prakash and Kang \[[@B19-cancers-12-00730],[@B29-cancers-12-00730]\]. The amount of *KIT* and *PDGFRA* mutations does not seem to be as low as in paediatric patients, but also not as high as in OA patients. Since we found no clear turning point, there seems to be more evidence for a gliding scale, where an increase in age also increases the probability of a *KIT/PDGFRA* mutated GIST \[[@B31-cancers-12-00730]\]. In two recent studies conducted in wildtype GIST patients, the reported median ages were 21 and 23 years, which supports the theory that most WT GISTs occur at a younger age \[[@B32-cancers-12-00730],[@B33-cancers-12-00730]\].

In our cohort, YA GIST patients tended to undergo surgery more often in an emergency setting compared to OA. The relatively high percentage of small-intestine localisations might account for this \[[@B34-cancers-12-00730]\]. Another possible explanation would be that the rarity of GIST at the YA age leads to a delay in (correct) diagnosis. Delay of diagnosis in sarcomas, especially at this age, remains a problem, and efforts to educate doctors and patients should be continued \[[@B35-cancers-12-00730]\].

In over half of these young adults, the impact of the disease on life was not documented in their file and therefore possibly not discussed. For these YA patients who are diagnosed with cancer in the prime time of their lives, it is essential to take psychosocial factors (e.g., relationships, fertility, sexuality, financial toxicity and workability) into account. With a five-year survival of 85%, these survivorship issues are not trivial.

The five-year OS reported in this study is in line with the 82.4% five-year OS reported by Fero et al. in a large cohort of AYA patients aged 13--39, with GIST \[[@B30-cancers-12-00730]\]. A study conducted in elderly (≥75 years) GIST patients reported a median OS of just 34 months \[[@B31-cancers-12-00730]\]. The five-year survival rate of YA in our cohort seemed superior to the survival rate of OA (85% vs. 76%), but this was not significant. Notably, there was a difference in median follow-up, and the influence of other age-related factors, such as comorbidities, was not corrected for and could also explain (a part of) the difference in survival rate.

As a side note, several Dutch databases with paediatric cancer patients were searched for GIST, and over the same time period, only one paediatric patient was diagnosed. This illustrates how extremely rare paediatric GIST is.

For future research, it would be interesting to compare separate molecular subgroups between the YA and OA patients, in order to find out if the differences between the age groups persist. However, since GIST in YA patients is rare, and molecular subgroups are therefore extremely small, this research question can only be answered in an international setting, with an adequate sample size. Although the data was obtained from the DGR, a database containing information on GIST patients diagnosed for 10 years, the rarity of YA GIST makes that the numbers are still relatively small. Moreover, when the DGR was established, it was not common practice to test for *NTRK* fusion genes and *BCOR* gene mutations. Despite these limitations, this study on YA GIST is the largest series of a national population, including mutational status. Given its therapeutic implications, it is recommended to test from now on the quadruple WT GISTs for *NTRK* (neurotrophic tyrosine kinase) fusion genes as part of standard care.

4. Materials and Methods {#sec4-cancers-12-00730}
========================

4.1. Patient Selection and Variables {#sec4dot1-cancers-12-00730}
------------------------------------

All patients who were 18 to 40 years old at diagnosis, who were diagnosed with GIST between January 2009 and January 2019 and who were registered in the Dutch GIST Registry (DGR) were included. The DGR is a prospectively maintained database, including patients ≥18 years with GIST treated in one of the five Dutch GIST centres (LUMC Leiden, Erasmus MC Rotterdam, UMC Groningen, Radboud UMC Nijmegen and the Netherlands Cancer Institute Amsterdam). Patient (age, gender, symptoms at diagnosis, presence of second malignancies and syndromic presentation), tumour (location, size, status at diagnosis (e.g., localized disease or metastatic disease), pathology (histology, mitotic rate and mutation status), treatment (surgery yes/no, surgery setting (e.g., emergency setting, planned operation for GIST and planned other surgery), (neo)adjuvant therapy yes/no) and follow-up data were obtained from the database. Furthermore, clinical, treatment and outcome data of all older adults (OA, \>40 years old) were collected from the DGR, to compare data between OA and YA. Within the comparison of tumour location, locations with less than 100 patients in the OA group were classified as 'other'. The DGR was approved by the local independent ethics committee (PTC14.0057). We adhered to the STROBE guidelines for cohort studies.

4.2. Pathology {#sec4dot2-cancers-12-00730}
--------------

GIST diagnosis was confirmed by positive immunohistochemistry (IHC) for CD117 and/or DOG1. Histology was described as spindle cell, epithelioid cell or mixed cell type. The required total count of mitoses is per 5 mm^2^ on the glass slide section. With the use of older model microscopes, 50 HPF was used which we considered semi-equivalent to 5 mm^2^. Low mitotic rate was defined as ≤ 5 mitoses/5 mm^2^ and high as \>5 mitoses/5 mm^2^. GIST specific mutations tested by Next Generation Sequencing (NGS) were *KIT, PDGFRA* and *BRAF*. Patients without *KIT/PDGFRA/BRAF* mutations and where no SDH analysis was performed were considered triple wildtype (WT). Patients without *KIT/PDGFRA/BRAF* mutations and SDHB deficiency (considered deficient in the absence of SDHB protein expression on IHC \[[@B36-cancers-12-00730]\]) were considered quadruple WT. Based on size, tumour site and mitotic activity, patients were subdivided into risk classification groups according to Miettinen's criteria \[[@B37-cancers-12-00730]\].

4.3. Quality of Life {#sec4dot3-cancers-12-00730}
--------------------

In this YA cohort, it was explored how often the psychosocial impact on life (e.g., depression, body image and relationships), influence on fertility and (in)ability to work was documented explicitly in the EPR by the medical oncologist. Whether or not this had been discussed with a patient was purely based on documentation in the EPR. Data on referral to a clinical geneticist were also collected.

4.4. Statistical Analyses and Outcome {#sec4dot4-cancers-12-00730}
-------------------------------------

Statistical analyses were performed by using SPSS Statistics (IBM Corporation, version 25.0, Armonk, NY, USA). Survival estimates were obtained, using the Kaplan--Meier method, and compared by the log-rank test. Overall survival (OS) was calculated from the date of diagnosis to the date of death or last follow-up. Follow-up time was estimated with the reversed Kaplan--Meier method. Two subgroups within the YA group were compared: 18--29 years vs. 30--40 years. The comparative analyses were done by using Fisher's exact test for categorical variables or Mann--Whitney U test for numeric variables.

5. Conclusions {#sec5-cancers-12-00730}
==============

YA with GIST are rare and differ from OA with GIST, but they also differ from paediatric GIST, as described in the literature. In this series, YA patients had a relatively high percentage of small intestine localisation and relatively often presented in the acute setting. Absence of both *KIT* and *PDGFRA* mutations was seen in 25% of YA patients. A relatively favourable five-year OS of 85% was observed.

The following is available online at <https://www.mdpi.com/2072-6694/12/3/730/s1>. Table S1: Adolescents and young adults (AYA) age-related GIST data in the existing literature.

###### 

Click here for additional data file.
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![Study flowchart. \* various reasons, such as metastatic disease, significant comorbidity, irresectable tumours or patients' preference. DGR = Dutch GIST Registry; YA = young adult; OA = older adult.](cancers-12-00730-g001){#cancers-12-00730-f001}

![Overall survival curve of the young adult (YA) patients and older adult (OA) patients. O = number of observed events; N = number of patients at risk.](cancers-12-00730-g002){#cancers-12-00730-f002}

![Distribution of mutation status among our young adult cohort \**ETV6-NTRK3* gene fusion. \# Wildtype for at least *KIT* and *PDGFR*.](cancers-12-00730-g003){#cancers-12-00730-f003}

cancers-12-00730-t001_Table 1

###### 

Clinical and tumour characteristics of total young-adult (YA) age group.

  --------------------------------------------------------------------------------------------
  Characteristic                                                           Total (%)
  ------------------------------------------------------------------------ -------------------
  **No. of YA Patients**                                                   52 (100)

  **Median age at Diagnosis (Range)**                                      35 years (18--40)

  **Gender**                                                               

  Male                                                                     28 (53.8)

  Female                                                                   24 (46.2)

  **Median Baseline Tumour Size in mm (Range)**                            60 (6--370)

  **Location**                                                             

  Gastric                                                                  24 (46.2)

  Small intestine                                                          24 (46.2)

  Rectum                                                                   3 (5.8)

  Oesophageal--cardiac junction                                            1 (1.9)

  **Syndromic Presentation**                                               

  No\                                                                      39 (90.7)\
  Yes                                                                      4 (9.3)

                  Neurofibromatosis 1                                      2

                  Carney triad                                             1

                  *KIT* exon 11 germline mutation                          1

                  Unknown                                                  9

  **Symptoms at Diagnosis** ^\*^                                           

  Active gastrointestinal bleeding                                         11 (22.4)

  Abdominal pain                                                           9 (18.4)

  Weight loss                                                              9 (18.4)

  Mass related symptoms (e.g., reflux, palpable mass, distended abdomen)   7 (14.3)

  Anaemia related symptoms                                                 6 (12.2)

  Acute abdomen                                                            6 (12.2)

  Nausea/vomiting                                                          4 (8.2)

  Change in bowel habits                                                   3 (6.1)

  Analysis vitamin B12 deficiency                                          1 (2.0)

  None (GIST coincidental finding)                                         8 (16.3)

  Unknown                                                                  3

  **Second Malignancies**                                                  

  No                                                                       49 (94.2)

  Yes                                                                      3 (5.8)

  **Tumour Status at Diagnosis**                                           

  Local disease                                                            45 (86.5)

  Metastasized                                                             7 (13.5)

  **Risk Classification**                                                  

  None\                                                                    2 (3.9)\
  Low                                                                      19 (37.3)

  Moderate                                                                 9 (17.6)

  High\                                                                    21 (41.2)\
  Unknown                                                                  1
  --------------------------------------------------------------------------------------------

^\*^ Multiple symptoms at diagnosis possible. GIST = Gastrointestinal stromal tumour.

cancers-12-00730-t002_Table 2

###### 

Pathology and tumour genetic results of young-adult patients.

  Characteristic                                      No. (%)
  --------------------------------------------------- -----------
  **Histology**                                       
  Spindle cell                                        37 (75.5)
  Epithelioid                                         3 (6.1)
  Mixed type                                          9 (18.4)
  Not reported                                        *3*
  **Baseline Mitotic Rate**                           
  Low (≤ 5/5 mm^2^)                                   35 (68.6)
  High (\> 5/5 mm^2^)                                 16 (31.4)
  Unknown                                             1
  **Mutation Status**                                 
  *KIT*                                               34 (69.4)
                   Exon 11 \*                         32
                   Exon 9                             3
  *PDGFRA*                                            3 (6.1)
                   D842V                              2
                   Non-D842V                          1
  SDH deficiency                                      4 (8.2)
  NF1 associated                                      2 (4.1)
  *ETV6-NTRK3* gene fusion                            1 (2.0)
  *KIT/PDGFRA* WT (*BRAF* and/or SDH not performed)   1 (2.0)
  Triple WT (SDH not performed)                       1 (2.0)
  Quadruple WT                                        3 (6.1)
  No mutational analysis performed                    3

\* One patient had both an exon 11 and exon 9 mutation in the primary tumour. NF1 = neurofibromatosis type 1; WT = wildtype.

cancers-12-00730-t003_Table 3

###### 

Clinical and tumour characteristics within the young-adult age group.

  -------------------------------------------------------------------------------------------
  Characteristic                                  18--29 Years\   30--40 Years\   *p*-Value
                                                  (*n* = 15)      (*n* = 37)      
  ----------------------------------------------- --------------- --------------- -----------
  **Median Age at Diagnosis (Range)**             26 (18--29)     38 (30--40)     

  **Gender**                                                                      0.07

  Male                                            5 (33.3)        23 (62.2)       

  Female                                          10 (66.6)       14 (37.8)       

  **Median Baseline Tumour Size in mm (Range)**   45 (14--170)    60 (6--370)     0.23

  **Primary Site Grouped**                                                        0.48

  Gastric                                         5 (33.3)        19 (51.4)       

  Small intestine                                 9 (60.0)        15 (40.5)       

  Other                                           1 (6.7)         3 (8.1)         

  **Histology**                                                                   0.74

  Spindle cell                                    12 (80.0)       24 (73.5)       

  Epithelioid                                     0 (0.0)         3 (8.8)         

  Mixed type                                      3 (20.0)        6 (17.6)        

  Unknown                                         0               3               

  **Tumour Status at Diagnosis**                                                  1.00

  Local disease                                   13 (87.7)       32 (86.5)       

  Metastasized                                    2 (13.3)        5 (13.5)        

  **Risk Category**                                                               0.53

  Low/moderate                                    7 (46.7)        23 (62.2)       

  High                                            7 (53.3)        14 (37.8)       

  Unknown                                         1               0               

  **Mutation Status**                                                             0.72

  *KIT*                                           10 (66.7)       24 (70.6)       

  *PDGFRA*                                        0 (0.0)         3 (8.8)         

  SDH deficient                                   2 (13.3)        2 (5.9)         

  NF1 associated                                  1 (6.7)         1 (2.9)         

  *ETV6-NTRK3* gene fusion                        0 (0.0)         1 (2.9)         

  WT (min. *KIT* and *PDGFRA*)\                   2 (13.3)\       3 (8.8)\        
  Unknown                                         0               3               

  **Baseline Mitotic Rate**                                                       0.32

  Low (≤ 5/5 mm^2^)                               8 (57.1)        27 (73.0)       

  High (\> 5/5 mm^2^)\                            6 (42.9)\       10 (27.0)\      
  Unknown                                         1               0               

  **Surgery**                                                                     0.41

  Yes\                                            14 (93.3)\      30 (81.1)\      
  No                                              1 (6.7)         7 (18.9)        

  **Patients who Received Surgery**               14 (93.3)       30 (81.1)       0.41

  **Resection Margin**                                                            0.26

  Negative (R0)                                   12 (85.7)       27 (96.4)       

  Positive (R1/R2)                                2 (14.3)        1 (3.6)         

  Unknown                                         0               2               

  **Tumour Rupture**                                                              1.00

  No                                              11 (84.6)       24 (80.0)       

  Yes                                             2 (15.4)        5 (20.0)        

  Unknown                                         1               1               
  -------------------------------------------------------------------------------------------

NF1 = neurofibromatosis type 1; WT = wildtype.

cancers-12-00730-t004_Table 4

###### 

Clinical and tumour characteristics in the young adult (YA) and older adult (OA) age groups.

  -------------------------------------------------------------------------------------------------------
  Characteristic                                  Total (%)\     YA (%)\       OA (%)\        *p*-Value
                                                  *n* = 1010     *n* = 52      *n* = 958      
  ----------------------------------------------- -------------- ------------- -------------- -----------
  **Median Age at Diagnosis (range)**             64 (18--95)    35 (18--40)   65 (41--95)    

  **Gender**                                                                                  0.89

  Male                                            533 (52.8)     28 (53.8)     505 (52.7)     

  Female                                          477 (47.2)     24 (46.2)     453 (47.3)     

  **Median Baseline Tumour Size in mm (Range)**   72 (1--1000)   60 (6--370)   73 (1--1000)   0.09

  **Primary Site Grouped**                                                                    0.03 \*

  Gastric\                                        604 (60.7)\    24 (46.2)\    580 (61.5)\    
  Small intestine\                                290 (29.1)\    24 (46.2)\    266 (28.2)\    
  Other                                           101 (10.2)     4 (7.7)       91 (10.3)      

  **Syndromic Presentation**                                                                  0.047 \*

  No                                              799 (96.7)     39 (90.7)     760 (97.1)     

  Yes                                             27 (3.3)       4 (9.3)       23 (2.9)       

  Unknown                                         184            9             175            

  **Tumour Status at Diagnosis**                                                              0.09

  Local disease                                   767 (76.0)     45 (86.5)     722 (75.4)     

  Metastasized                                    242 (24.0)     7 (13.5)      235 (24.6)     

  Unknown                                         1              0             1              

  **Histology**                                                                               0.26

  Spindle cell                                    739 (78.3)     37 (75.5)     702 (78.4)     

  Epithelioid                                     94 (10.0)      3 (6.1)       91 (10.2)      

  Mixed type                                      111 (11.8)     9 (18.4)      102 (11.4)     

  Unknown                                         66             3             63             

  **Baseline Mitotic Rate**                                                                   0.76

  Low (≤5/5 mm^2^)                                491 (66.4)     35 (68.6)     462 (66.2)     

  High (\>5/5 mm^2^)                              252 (33.6)     16 (31.4)     236 (33.8)     

  Unknown                                         261            1             260            

  **Mutation Status**                                                                         0.001 \*

  *KIT*                                           630 (75.9)     34 (69.4)     596 (76.3)     

  *PDGFRA*                                        106 (12.8)     3 (6.1)       103 (13.2)     

  *BRAF*                                          1 (0.1)        0             1 (0.1)        

  SDH deficiency                                  13 (1.6)       4 (8.2)       9 (1.2)        

  NF1 associated                                  16 (1.9)       2 (4.1)       14 (1.8)       

  *ETV6-NTRK3* gene fusion                        1 (0.1)        1 (2.0)       0              

  Wildtype (at least *KIT* and *PDGFRA*)          63 (7.6)       5 (10.2)      58 (7.4)       

  Unknown                                         180            3             177            

  ***KIT/PDGFRA* vs. non-*KIT/PDGFRA***                                                       0.008 \*

  *KIT/PDGFRA*                                    736 (88.7)     37 (75.5)     699 (89.5)     

  Non-*KIT/PDGFRA*                                94 (11.3)      12 (24.5)     82 (10.5)      

  **Patients who Received Surgery**               793 (78.5)     44 (84.6)     749 (78.2)     0.30

  **Surgery Setting**                                                                         0.06

  Planned operation                               712 (90.7)     36 (81.8)     676 (91.2)     

  Emergency setting                               73 (9.3)       8 (18.2)      65 (8.8)       

  Unknown                                         8              0             8              
  -------------------------------------------------------------------------------------------------------

\* *p*-value \< 0.05 was considered significant; NF1 = neurofibromatosis type 1.
